Home
contact us  /  email
about us
portfolio
team
news
Oct 11, 2018
Otsuka and Proteus sign 5-year, $88M digital pill partnership
Fierce Biotech
Otsuka Pharmaceutical and Proteus Digital Health have re-upped their global smart-tablet partnership for another five years, aiming to develop a new generation of ingestible sensors.   more >>
Sep 25, 2018
Coherus Biosciences receives European Commission approval for udenyca™ (pegfilgrastim biosimilar)
GLOBE NEWSWIRE
Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar.   more >>
Sep 11, 2018
Invuity announces definitive agreement to be acquired by Stryker Corporation for $7.40 per share in cash
GLOBE NEWSWIRE
Invuity, Inc. (NASDAQ: IVTY), a leading medical technology company focused on advanced surgical devices to enable better visualization, today announced it has entered into a definitive agreement with Stryker Corporation (NYSE:SYK), pursuant to which Stryker will acquire all of the outstanding shares of Invuity for $7.40 per share in cash   more >>
Nov 14, 2017
The Digital Pill Era Is Here — And It Could Help Solve a $300 Billion Health Care Problem
Fortune
The Food and Drug Administration (FDA) on 11/13/2017 approved the first ever drug-digital tracking tool hybrid for the U.S. market.   more >>
Feb 01, 2016
Coherus announces chs-1701 (neulasta® biosimilar) met both primary endpoints in registration-enabling immunogenicity study
Cherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS) today announced that CHS-1701, a proposed biosimilar of Neulasta® (pegfilgrastim), met both primary endpoints in a double-blind, randomized, two-period, parallel-arm clinical study in 303 healthy subjects.   more >>
Nov 16, 2015
Invuity, Inc. (Nasdaq: IVTY) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire
Invuity, Inc. (IVTY), an advanced medical technology company focused on developing Intelligent Photonics™ devices will visit the Nasdaq MarketSite in Times Square in celebration of both its initial public offering earlier this year and the successful launch of its Hidden Scar™ Surgery program for breast cancer surgery, a part of the company's broader women's health initiative.   more >>
Jun 11, 2015
Invuity Announces Pricing of Initial Public Offering
PR Newswire
SAN FRANCISCO, June 11, 2015 /PRNewswire/ -- Invuity, Inc. today announced the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts and commissions   more >>
Nov 06, 2014
Coherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock
Globe Newswire
Coherus BioSciences, Inc. (Nasdaq:CHRS) announced today the pricing of its initial public offering of 6,296,300 shares of its common stock at a public offering price of $13.50 per share   more >>
Apr 11, 2013
NASDAQ Welcomes Chimerix, Inc. to The NASDAQ Stock Market
The NASDAQ OMX Group, Inc.
The NASDAQ OMX Group, Inc. announces an IPO of Chimerix (CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need.   more >>
00, 0000
The Digital Pill Era Is Here—And It Could Help Solve a $300 Billion Health Care Problem
Fortune
The Food and Drug Administration (FDA) on 11/14/17 approved the first ever drug-digital tracking tool hybrid for the U.S. market.   more >>
News archive >>

 
 
© Helix Ventures 2008 – 2015   /   about us   /   portfolio   /   team   /   news   /   contact us